Nouscom
OverviewSuggest Edit
Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.
| Type | Private | |
| Founded | 2015 | |
| HQ | Basel, CH | Map |
| Website | nouscom.com |
Recent NewsAll News
- Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy
- Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer
- Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability
- Nouscom Strengthens Its Management Team
Latest Updates
| Employees (est.) (Jul 2021) | 32 | |
| Cybersecurity rating | D | More |
Key People/Management at Nouscom
Riccardo Cortese
Co-Founder
Elisa Scarselli
Chief Scientific Officer and Co-Founder
Marina Udier
Chief Executive Officer & Board Director
Stefano Colloca
Co-Founder & Advisor
Tiffany Muller
VP, Finance
Patricia Delaite
Chief Medical Officer
Nouscom Office Locations
Nouscom has offices in Basel and Roma
Basel, CH (HQ)
18 Bäumleingasse
Roma, IT
100 Via di Castel Romano
Nouscom Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Nouscom total Funding | $62.6 m |
Nouscom latest funding size | $49 m |
Time since last funding | 4 years ago |
Nouscom investors | Versant Ventures, 5AM Ventures, Abingworth, LSP BioVentures, LSP |
Nouscom's latest funding round in November 2017 was reported to be $49 m. In total, Nouscom has raised $62.6 m
Nouscom Cybersecurity Score
Nouscom Online and Social Media Presence
Nouscom's Trends
Nouscom News and Updates
March 11, 2021
Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy
BASEL, Switzerland, March 11, 2021 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today announces it has received approval from the Spanish National Agency of Medicines and Medical Devices (Agencia Española...
December 11, 2020
Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer
BASEL, Switzerland, Dec. 11, 2020 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized genetic cancer vaccines, today announces that it has appointed Göran Ando, MD as the new Chairman of its Board of Directors. Nouscom also appointed...
July 22, 2020
Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability
BASEL, Switzerland, July 22, 2020 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the publication of new research describing the cutting-edge science and rationale for the design of NOUS-209 and...
February 26, 2020
Nouscom Strengthens Its Management Team
BASEL, Switzerland, Feb. 26, 2020 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that it has appointed Marina Udier, PhD, as Chief Executive Officer (CEO) and Patricia Delaite, MD, as Chief Medical...
December 09, 2019
Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
BASEL, Switzerland, Dec. 9, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating its lead candidate, NOUS-209. In this...
June 03, 2019
Nouscom - IND for NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors
BASEL, Switzerland, June 3, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational New Drug (IND) application for the first clinical trial of its lead candidate NOUS-209 has...
Nouscom Blogs
June 22, 2021
Dr. Anna Morena D’alise will join as Expert Speaker at the Next Generation Cancer Vaccine Development Summit
Our head of Preclinical and Clinical Immunology Anna Morena D’alise will join as Expert Speaker at the Next Generation Cancer Vaccine Development Summit from September 7 – 9, 2021. You can register your place here: https://cancer-vaccine-development.com/take-part/register/
L'articolo Dr. Anna Morena…
May 18, 2021
Dr. Marina Udier will join a live session at the 21st BioEquity Europe on Tuesday, May 18, 11:30 am CET.
The Next aCGT Europe Needs to Leapfrog — How? Follow the link below for more details. https://lnkd.in/dpAnmJZ
L'articolo Dr. Marina Udier will join a live session at the 21st BioEquity Europe on Tuesday, May 18, 11:30 am CET. proviene da Nouscom.
March 09, 2021
Nouscom is presenting at the virtual Spring Private Company Showcase 2021 on March 11th
Find out more about the program and register here: Spring Private Company Showcase « Solebury Trout Access
L'articolo Nouscom is presenting at the virtual Spring Private Company Showcase 2021 on March 11th proviene da Nouscom.
March 09, 2021
Nouscom is presenting at the Biocapital Europe 2021 on March 11th
Find out more about the program and register here: https://www.biocapitaleurope.com/programme/
L'articolo Nouscom is presenting at the Biocapital Europe 2021 on March 11th proviene da Nouscom.
December 08, 2020
Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an anti-tumor immune response via lysis and crosspresentation of locally expressed endogenous tumor antigens…
December 01, 2020
New viral vectors for infectious diseases and cancer
ABSTRACT – Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into the current approaches of viral vectored genetic vaccines. In recent years, key improvements to the vacci…
Nouscom Frequently Asked Questions
When was Nouscom founded?
Nouscom was founded in 2015.
Who are Nouscom key executives?
Nouscom's key executives are Riccardo Cortese, Elisa Scarselli and Marina Udier.
How many employees does Nouscom have?
Nouscom has 32 employees.
Who are Nouscom competitors?
Competitors of Nouscom include Talaris Therapeutics, Orchard Therapeutics and Fauna Bio.
Where is Nouscom headquarters?
Nouscom headquarters is located at 18 Bäumleingasse, Basel.
Where are Nouscom offices?
Nouscom has offices in Basel and Roma.
How many offices does Nouscom have?
Nouscom has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies